Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Xigen SA

Xigen's PhII Success In Ocular Inflammation Opens Doors

Xigen's innovative JNK inhibitor, brimapitide, the first peptide to be delivered subconjunctivally for post-surgical ocular inflammation, has met its primary endpoint in a Phase II study – a vital goal in the Swiss firm's long-term plan for the product.

Ophthalmic Clinical Trials

Appointments: Shire, Allergan, Variant, Arix Bioscience, Marathon Pharmaceuticals, Enterome Bioscience and Artios Pharma

This week's roundup includes executive appointments by Artios Pharma, Tocagen, Enterome Bioscience and Shire, which has named various people to its oncology franchise team, and board appointments by Allergan and Variant Pharmaceuticals, which has appointed a former senior executive from Johnson & Johnson to its board of directors.

Appointments BioPharmaceutical

Hearing Therapy Pioneer Auris Medical Gets $50 Million Series C Financing

Auris Medical AG has completed Europe’s largest biotech investing round so far this year, led by Sofinnova Partners and Sofinnova Ventures, and hopes to advance the development of new otologic drugs for hearing dysfunction.

BioPharmaceutical Switzerland

Auris raises $50.5m for inner ear drugs

Swiss inner ear therapeutics developer Auris Medical, which has a US office in Chicago, raised CHF 47.1 million ($50.5 million) in a Series C venture funding round to take its tinnitus and hearing loss drugs into Phase III clinical trials and finance commercial activities.

Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Xigen SA
  • Senior Management
  • Christophe Bonny, PhD, CEO
    Elmar Scharli, CFO
    Dennis J Church, PhD, Dir., Research & Alliance
  • Contact Info
  • Xigen SA
    Phone: (41) 21 321 10 80
    17 rue des Terreaux
    Lausanne, 1003
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register